Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02475213
Title Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors MacroGenics
Indications

head and neck squamous cell carcinoma

melanoma

lung non-small cell carcinoma

Therapies

MGA271 + Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.